A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Bristol-Myers Squibb
Arcus Biosciences, Inc.
Pfizer
Pfizer
Qilu Pharmaceutical Co., Ltd.
Genentech, Inc.
Tyligand Pharmaceuticals (Suzhou) Limited
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
University of California, San Diego
Jiangsu Hansoh Pharmaceutical Co., Ltd.
ImmunityBio, Inc.
Eli Lilly and Company
Shanghai Jiao Tong University School of Medicine
Canadian Cancer Trials Group
Cantargia AB
University of California, San Francisco
Incyte Corporation
AstraZeneca
Gilead Sciences
Columbia University
University of Louisville
Masonic Cancer Center, University of Minnesota
H. Lee Moffitt Cancer Center and Research Institute
Ziekenhuis Oost-Limburg
University of Miami
Chonnam National University Hospital
University of Alabama at Birmingham
Oncology Specialists, S.C.
Medical University of Vienna
University of Chicago
Veeda Oncology
Korean South West Oncology Group
Krankenhaus Nordwest
Columbia University
Sanofi
National Cancer Center, Korea
National Cancer Center, Korea
Sanofi
The First Affiliated Hospital of Guangzhou Medical University
Sanofi
Mt. Sinai Medical Center, Miami
Swedish Medical Center
Integrated Community Oncology Network